Inflammasomes & Parkinson's Disease
Parkinson's disease (PD) is a long-term, progressive, neurodegenerative disease affecting approximately 1 million people in the US and generally occurring in people over 60 years of age. It is characterized by death of cells in the substantia nigra of the brain, leading to a reduction in levels of dopamine. Clinical symptoms include tremors, stiffness, and slow movement.
The precise cause of Parkinson's disease is unknown, although genetics and environmental exposures are implicated. Like many other neurodegenerative diseases, PD is thought to be a multi-factorial disease with many neurotoxins found in the brains of patients with the disease. Amongst these, the protein α-synuclein is considered a key protein and a target for drug development. However, also present at high levels are various forms of complement, iron accumulation, retrotransposons, gamma interferon, and reactive oxygen species. There is increasing evidence that these agents all contribute to the neuroinflammation that characterize PD.
All these neurotoxic elements, including α-synuclein, induce inflammasome activation, and markers of inflammasome activation (IL-1β, IL-18, and caspase-1) are elevated in the CSF of patients with Parkinson’s disease. Systemic levels of α-synuclein and markers of inflammasome activation are correlated with motor severity and progression of disease.
While targeting a specific element (such as α-synuclein) may be successful, we believe that inflammasome activation, the common pathway for neuroinflammation that the various toxins cause, may be a more promising approach.
References
-
Blum-Degan D et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 1995;202(1-2)17-20
-
Diaz V et al. The role of oxidative stress in Parkinson’s disease. J Parkinson's disease 2013;3(4):461-469
-
Fan Z et al. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease. J Neuro Inflamm 202017:11
-
Ferrari DP, Bortolanza M Del Bel EA Interferron gamma’s involvement in the neuroinflammation associated with Parkinson’s disease and L-Dopa induced dyskinesia. Neuro Tox. Res. 2021 Jun;39(3):705-719
-
Gomez-Benito M et al. Modelling Parkinson’s disease with alpha synuclein protein. Front Pharmacol 2020;11:356
-
Loeffler DA Camp DA and Vonant SB. Complement activation in Parkinson’s disease substantia nigra: an immunocytochemical study. J Neuroinflamm 2006;3:29
-
Marras C et al. Prevalence of Parkinson’s disease in North America 2018 ;4:21
-
Plaff AL et al. An increased burden of highly active retrotransposition competent L1s is associated with Parkinson’s disease risk and progression in the PPMI cohort. Int. J Mol Sci. 2020;21(18):6562
-
Qin X-Y et al. Aberrations in peripheral inflammatory cytokine levels in Parkinson’s disease. A systematic review and meta analysis. JAMA Neurol. 2016;73(11)1316-1324
-
Research and Markets. Parkinson’s disease drugs. Global market trajectory and analytics 2021
-
Wolozin B et al. Iron and Parkinson’s disease. Neuroscientist 2002 8(1):22-32
Market Opportunity
Parkinson’s disease affects approximately 1 million people in the US. The drugs used to treat it are designed to supplement dopamine levels and hence mask the symptoms but do not affect the progression of the disease. Unfortunately, as the disease progresses these drugs become less effective. The drugs used (formulations of L-DOPA and monoamine oxidase inhibitors) have been off-patent for many years and are relatively inexpensive. The total US drug sales for PD was $1.4B in 2020, while the annual direct cost of medical care for patients with PD exceeded $25B. A drug therapy that reduces or prevents the progression of the disease (and reduces overall care costs) would be extremely valuable.